INTEGRA LIFESCIENCES HOLDINGS CORP — Form 10-Q
Filed July 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 42/100
What the filing says
Integra LifeSciences appointed Stuart Essig as President and CEO effective May 1, 2026 under a 3-year employment agreement with base salary $1,075,000, target bonus of 125% of base salary, and equity grants worth $8,000,000 (RSU and option awards each worth $4,000,000). Simultaneously, the company terminated Mojdeh Poul (the prior CFO) without cause, providing severance of 2.0× base salary payable over 2 years ($254,151 lump sum), pro-rata 2026 bonus of $312,375, COBRA continuation for 18 months, legal fee reimbursement up to $25,000, and forfeiture of 412,518 unvested RSUs and 163,471 unvested options (vested options remain exercisable for 6 months).
Why this rating
CEO transition is significant operationally but severance cost (~$850K+ over 2 years) is ~0.09% of $925M market cap—moderate. Equity grants to new CEO are material incentive structure; Poul departure routine. No dramatic shift in business trajectory disclosed.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.